Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05776069 · ClinicalTrials.gov registry record · Phase 1
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
A Phase 1 study of Von Willebrand Diseases, sponsored by Vega Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 20
- Study locations
NCT05776069: Recruiting Phase 1 study of Von Willebrand Diseases, sponsored by Vega Therapeutics.
NCT05776069 is a Phase 1 study of Von Willebrand Diseases that is actively recruiting participants, run by Vega Therapeutics. The registered enrollment target is 116 participants, below the 715-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05776069, a Phase 1 study of Von Willebrand Diseases, is actively recruiting participants, sponsored by Vega Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 20
- Study locations
Study Summary
The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.
Primary Outcome
Incidence, nature and severity of adverse events (AEs) and serious adverse events (SAEs), including dose-limiting toxicities (DLTs).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG VGA039
Study Locations (20)
Ontario
- Hamilton Health Sciences Corporation - Hamilton
- Queens University - Kingston
- St. Michaels Hospital - Toronto
California
- Orthopedic Institute for Children (UCLA) - Los Angeles
- UC Davis Medical Center - Sacramento
São Paulo
- Hemocentro Unicamp - Campinas
- Hospital das Clinicas - USP Endereco - São Paulo
Colorado
- University of Colorado School of Medicine - Aurora
Georgia
- Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory - Atlanta
North Carolina
- Science 37, Inc. - Morrisville
Pennsylvania
- Hemophilia Center of Western PA - Pittsburgh
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
What NCT05776069 shows while recruiting
NCT05776069 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 715-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Von Willebrand Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05776069 names 20 study sites across 16 states, led by Ontario, California, São Paulo.
Frequently Asked Questions
What is clinical trial NCT05776069 about?
NCT05776069 is a clinical study titled "Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)". The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.
What is the current status of trial NCT05776069?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2023-03-16. Estimated completion is 2029-12.
What conditions does trial NCT05776069 study?
This clinical trial studies the following conditions: Von Willebrand Diseases.
What interventions are being tested in trial NCT05776069?
The interventions under investigation include: Placebo (OTHER), VGA039 (DRUG).
Who is sponsoring clinical trial NCT05776069?
This trial is sponsored by Vega Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05776069 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
RECRUITING
-
Von Willebrand Factor in Pregnancy (VIP) Study
RECRUITING
-
ATHN 9: Severe VWD Natural History Study
ACTIVE NOT RECRUITING
-
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI